The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Ablative treatment for colorectal liver metastases with curative intent: insights from CIEMAR
Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg, Hamburg, Germany, shares insights in the CIRSE Emprint Microwave Ablation Registry (CIEMAR) (NCT03775980), which evaluated ablative treatment for colorectal liver metastases with curative intent. Standard risk factors were still relevant, including the ablation zone and the size of metastases, and ablative treatment was able to achieve between 6 and 9 months without any further treatment to the liver, showing good disease control. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
